Prostate Cancer Screening Hits the Streets With the 'Man Van'

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 18, 2025.

By Randy Dotinga HealthDay Reporter

TUESDAY, Feb. 18, 2025 -- A mobile "Man Van" screening program detected dozens of prostate cancer cases in disadvantaged neighborhoods of London, researchers report.

A team led by Dr. Masood Moghul of Royal Marsden Hospital in London reported its findings at the American Society of Clinical Oncology's annual Genitorurinary Cancers Symposium in San Francisco last week.

The screening was offered between January 2023 and January 2024. Led by nurses, the roving clinical unit offered prostate-specific antigen (PSA) tests as well as general health check-ups to men who were invited due to their high risk.

Of 3,379 men (average age: 59) who agreed to be screened, 310 had further exams due to suspicion of prostate cancer, and 127 had biopsies. In all, 36.4% of participants were non-white, including 16.7% who were Black men.)

In all, 81 men (2.8%) were diagnosed with clinically significant prostate cancer, and they were managed with various treatments.

One man was diagnosed with bladder cancer, 43 (2%) with diabetes, and 207 (11%) with pre-diabetes.

"With a streamlined and more efficient service we have maintained high uptakes for health checks a willingness to engage with health improvement measures from deprived and ethnic minority groups," the researchers wrote.

In 2020, prostate cancer was the second most commonly diagnosed cancer and the second-leading cause of cancer-related deaths among men worldwide.

In both the United States and the U.K., screening guidelines often emphasize consulting with a doctor to assess a man's prostate cancer risk.

But this approach, researchers said, may create an additional barrier for those already at higher risk, potentially delaying diagnosis until the disease is more advanced and harder to treat.

Research presented at meetings is typically considered preliminary until published in a peer-reviewed journal.

Sources

  • American Society of Clinical Oncology meeting, Feb. 13-15, 2025, San Francisco

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-02-19 06:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords